Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alnylam Pharmaceut (ALNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,075,173
  • Shares Outstanding, K 106,304
  • Annual Sales, $ 74,910 K
  • Annual Income, $ -761,500 K
  • 60-Month Beta 2.61
  • Price/Sales 124.05
  • Price/Cash Flow N/A
  • Price/Book 6.79

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -2.20
  • Number of Estimates 5
  • High Estimate -2.10
  • Low Estimate -2.38
  • Prior Year -1.41
  • Growth Rate Est. (year over year) -56.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
79.79 +6.99%
on 04/18/19
96.08 -11.15%
on 04/01/19
+0.85 (+1.01%)
since 03/22/19
3-Month
74.29 +14.91%
on 02/08/19
96.08 -11.15%
on 04/01/19
+4.58 (+5.67%)
since 01/24/19
52-Week
60.27 +41.65%
on 12/24/18
124.21 -31.27%
on 08/31/18
-9.36 (-9.88%)
since 04/24/18

Most Recent Stories

More News
After Yesterday's Decline of 4.29%, Alnylam Pharmace Offers Investors Better Value

Alnylam Pharmace (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $80.94 to a high of $85.34. Yesterday, the shares fell 4.3%, which took the trading range below the 3-day low of...

ALNY : 85.37 (-2.33%)
Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran

Alnylam (ALNY) initiates phase III study on lumasiran and also reports new positive efficacy results from the ongoing phase II open-label extension (OLE) study on the same.

MDCO : 29.46 (+0.31%)
ALNY : 85.37 (-2.33%)
NVS : 77.82 (+2.53%)
REGN : 340.46 (-1.07%)
Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran

Alnylam (ALNY) reports complete positive results from the phase III ENVISION study of givosiran for the treatment of acute hepatic porphyria.

MDCO : 29.46 (+0.31%)
ALNY : 85.37 (-2.33%)
NVS : 77.82 (+2.53%)
REGN : 340.46 (-1.07%)
Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study

--a^' Lumasiran Treatment Resulted in 72 Percent Mean Maximal Reduction in Urinary Oxalate Relative to Phase 1/2 Baseline -

ALNY : 85.37 (-2.33%)
Best Relative Performance in the Biotechnology Industry Detected in Shares of Alder Biopharmac (ALDR , ALNY , RARE , VCYT , EXAS )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

RARE : 67.73 (-0.09%)
ALDR : 13.68 (-0.51%)
ALNY : 85.37 (-2.33%)
Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria

--a^' Treatment Effect Includes a 90 Percent Median Decrease in Composite AAR Relative to Placebo, with 50 Percent of Givosiran Patients Attack-Free -

ALNY : 85.37 (-2.33%)
New Research: Key Drivers of Growth for Sonos, Alnylam Pharmaceuticals, Bright Horizons Family Solutions, Brightcove, Alexco Resource, and Horace Mann Educators -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Sonos, Inc. (NASDAQ:SONO),...

BCOV : 8.74 (+1.39%)
ALNY : 85.37 (-2.33%)
HMN : 37.65 (+1.05%)
SONO : 10.99 (-2.31%)
AXU : 0.96 (+0.58%)
BFAM : 127.61 (-0.36%)
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

Sector ETF report for PBE

PBE : 52.23 (-1.29%)
CELG : 93.10 (-0.61%)
ILMN : 314.52 (-2.34%)
IBB : 105.64 (-1.09%)
ALNY : 85.37 (-2.33%)
XBI : 85.86 (-1.22%)
-0.5% Return Seen to Date on SmarTrend Alnylam Pharmace Call (ALNY)

SmarTrend identified an Uptrend for Alnylam Pharmace (NASDAQ:ALNY) on March 5th, 2019 at $88.84. In approximately 1 month, Alnylam Pharmace has returned 0.45% as of today's recent price of $88.44.

ALNY : 85.37 (-2.33%)
Watch for Alnylam Pharmace to Potentially Rebound After Falling 2.70% Yesterday

Alnylam Pharmace (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $88.44 to a high of $91.53. Yesterday, the shares fell 2.7%, which took the trading range below the 3-day low of...

ALNY : 85.37 (-2.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade ALNY with:

Business Summary

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies,...

See More

Key Turning Points

2nd Resistance Point 88.45
1st Resistance Point 86.91
Last Price 85.37
1st Support Level 84.25
2nd Support Level 83.13

See More

52-Week High 124.21
Fibonacci 61.8% 99.79
Fibonacci 50% 92.24
Last Price 85.37
Fibonacci 38.2% 84.70
52-Week Low 60.27

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar